Q1 Earnings Estimate for MDxHealth Issued By William Blair

MDxHealth SA (NASDAQ:MDXH) – Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of MDxHealth in a research note issued to investors on Wednesday, February 26th. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of ($0.13) for the quarter. The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.05) EPS.

Separately, Piper Sandler reduced their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, November 7th.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $1.82 on Friday. The company has a 50-day moving average of $2.01 and a 200-day moving average of $2.20. The firm has a market cap of $86.06 million, a price-to-earnings ratio of -1.20 and a beta of 1.34. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. MDxHealth has a twelve month low of $1.55 and a twelve month high of $3.85.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. The firm had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new stake in MDxHealth during the 4th quarter worth about $25,000. Oppenheimer & Co. Inc. increased its position in shares of MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after acquiring an additional 10,000 shares in the last quarter. FAS Wealth Partners Inc. raised its holdings in shares of MDxHealth by 49.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock valued at $58,000 after acquiring an additional 8,100 shares during the period. XTX Topco Ltd acquired a new stake in shares of MDxHealth during the fourth quarter valued at approximately $63,000. Finally, Delta Investment Management LLC purchased a new stake in shares of MDxHealth in the 4th quarter valued at approximately $81,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.